1613641-69-2

Avacincaptad pegol, which is a pegylated aptamer, has garnered significant attention as a C5 complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA)[1][2].

[1] Rehan M Hussain, et al. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. DOI:10.1080/14712598.2018.1513486
[2] Glenn J Jaffe, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. DOI:10.1016/j.ophtha.2020.08.027